Real World Study of Platinum Containing Dual Drug Chemotherapy Followed by Large Fractionated Radiotherapy Combined withTislelizumab in Stage IIIB/C-IV Non-small Cell Lung Cancer Patient

Prior treatment

• Patients who have previously received systemic chemotherapy, or adjuvant or neoadjuvant therapy, and the time from the last treatment to recurrence is less than 3 months;

Other illness

• Patients with uncontrolled autoimmune diseases;
• Patients who have experienced autoimmune reactions within the past 6 months and whose conditions have not improved or are unstable after corresponding treatments, such as pneumonia, thyroiditis, myocarditis, etc. that have not stabilized after treatment;
• Patients with known allergies or contraindications to the study drug or its excipients;
• Patients whose comorbidities or other conditions may affect compliance with the protocol or are deemed unsuitable for participation in this study by the investigator.

Other

• Pregnant or lactating female patients, or female patients of childbearing potential with a positive baseline pregnancy test;
• Female patients of childbearing potential or male patients with reproductive plans who are unwilling to use effective contraception during the entire trial period and for 6 months after the end of the trial;

• Age 18-75 years old, gender is not limited;
• Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
• Patients with stage IIIB/C-IV non-squamous non-small cell lung cancer confirmed by cytology or histology;
• Tumor histology or hematology confirms no EGFR mutations and no mutations or positive driver genes for ALK, BRAF, ROS1, RET, MET, etc or Targeted drug therapy leads to drug resistance progression